Accuracy and Precision of the True Vie I3 Continuous Glucose Monitoring System: an Open Label, Multi-Center Trial

NCT05806554 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 159

Last updated 2025-11-25

No results posted yet for this study

Summary

The purpose of the investigation is to evaluate the performance of the I3 CGM according to the FDA's special controls for iCGM.

Conditions

Interventions

DEVICE

Continuous glucose monitoring device

Continuous glucose monitoring device

Sponsors & Collaborators

  • Integrated Medical Development

    collaborator INDUSTRY
  • Sinocare

    lead INDUSTRY

Principal Investigators

  • Ron Brazg, MD · RCRC

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-19
Primary Completion
2024-06-13
Completion
2024-10-22
FDA Device
Yes

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05806554 on ClinicalTrials.gov